坏疽性脓皮病系统合并症的研究进展

doi:10.35541/cjd.20240424

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (4): 369-373.doi: 10.35541/cjd.20240424

坏疽性脓皮病系统合并症的研究进展

许秋云,纪超

福建医科大学附属第一医院皮肤科，福州 350005

收稿日期:2024-08-09 修回日期:2025-02-18 发布日期:2025-04-03
通讯作者: 纪超 E-mail:jichaofy@fjmu.edu.cn
基金资助:
福建省自然科学基金（2023J01618）；福建省免疫性皮肤病临床医学研究中心（2022Y2003）

Pyoderma gangrenosum-related systemic complications

Xu Qiuyun, Ji Chao

Received:2024-08-09 Revised:2025-02-18 Published:2025-04-03
Contact: Ji Chao E-mail:jichaofy@fjmu.edu.cn
Supported by:
Natural Science Foundation of Fujian Province （2023J01618）; Fujian Provincial Clinical Research Center for Immune Skin Diseases （2022Y2003）

摘要/Abstract

摘要： 【摘要】坏疽性脓皮病是一种自身炎症性疾病，属于中性粒细胞性皮肤病。常表现为快速发展的疼痛性皮肤溃疡，其溃疡特征为边界破坏和周围红斑。坏疽性脓皮病的病因尚不清楚，通常与多种其他免疫介导的疾病和多种潜在疾病相关，最常见的是炎症性肠病、血液疾病和恶性肿瘤、自身炎症综合征和炎症性关节炎等。本文综述坏疽性脓皮病相关系统合并症的研究进展。

关键词: 坏疽性脓皮病, 系统合并症, 炎症性肠病, 治疗, 发病机制, 生物制剂, JAK抑制剂

Abstract: 【Abstract】 Pyoderma gangrenosum （PG） is an autoinflammatory disorder that belongs to neutrophilic dermatosis. It often presents as a rapidly developing painful cutaneous ulcer, which is characterized by disruption of the border and peripheral erythema. The exact etiology of PG remains unknown, but it is often associated with various immune-mediated disorders. PG is associated with a wide range of underlying disorders, with inflammatory bowel disease, hematological diseases and malignancies, autoinflammatory syndromes and inflammatory arthritis as the most common underlying disorders. This review summarizes PG-related systemic complications.

Key words: Pyoderma gangrenosum, Systemic comorbidities, Inflammatory bowel disease, Therapy, Pathogenesis, Biologic agents, JAK inhibitor

许秋云纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 中华皮肤科杂志, 2025,58(4):369-373. doi:10.35541/cjd.20240424

Xu Qiuyun, Ji Chao. Pyoderma gangrenosum-related systemic complications[J]. Chinese Journal of Dermatology, 2025, 58(4): 369-373.doi:10.35541/cjd.20240424

参考文献 62

［1］	May MR, Rübben A, Lennertz A, et al. Dealing with corticosteroid and high⁃dose cyclosporine therapy in a pyoderma gangrenosum patient contracting a COVID⁃19 infection［J］. J Pers Med, 2022,12（2）:173. doi: 10.3390/jpm12020173.
［2］	Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum［J］. Nat Rev Dis Primers, 2020,6（1）:81. doi: 10.1038/s41572⁃020⁃0213⁃x.
［3］	胡清洁, 周敏, 姚煦. 坏疽性脓皮病36例临床特点分析及PARACELSUS评分与Delphi标准的比较［J］. 中华皮肤科杂志, 2023,56（5）:410⁃414. doi: 10.35541/cjd.20220825.
［4］	Zhao H, Sengupta SK, Haddadin O, et al. Effects of comorbidities on delayed wound healing in patients with pyoderma gangrenosum［J］. J Eur Acad Dermatol Venereol, 2024. doi: 10.1111/jdv.20457.
［5］	Kridin K, Damiani G, Ludwig RJ, et al. Estimating the odds of ulcerative colitis⁃associated pyoderma gangrenosum: a population⁃based case⁃control study［J］. Dermatology, 2021,237（3）:323⁃329. doi: 10.1159/000512931.
［6］	Kridin K, Damiani G, Ludwig RJ, et al. Quantification of the relationship between pyoderma gangrenosum and Crohn's disease: a population⁃based case⁃control study［J］. Scand J Gastroenterol, 2020,55（7）:814⁃818. doi: 10.1080/00365521. 2020.1786849.
［7］	Ben Abdallah H, Fogh K, Vestergaard C, et al. Pyoderma gangrenosum and interleukin inhibitors: a semi⁃systematic review［J］. Dermatology, 2022,238（4）:785⁃792. doi: 10.1159/00051 9320.
［8］	Antonelli E, Bassotti G, Tramontana M, et al. Dermatological manifestations in inflammatory bowel diseases［J］. J Clin Med, 2021,10（2）:364. doi: 10.3390/jcm10020364.
［9］	Argüelles⁃Arias F, Castro⁃Laria L, Lobatón T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease［J］. Dig Dis Sci, 2013,58（10）:2949⁃2954. doi: 10.1007/s10620⁃013⁃2762⁃2.
［10］	van Loo G, Bertrand M. Death by TNF: a road to inflammation［J］. Nat Rev Immunol, 2023,23（5）:289⁃303. doi: 10.1038/s41577⁃022⁃00792⁃3.
［11］	Holmes Z, Nguyen J, Courtney A, et al. Treatment of severe, refractory pyoderma gangrenosum with infliximab, adalimumab and intravenous immunoglobulin［J］. Australas J Dermatol, 2023,64（3）:433⁃435. doi: 10.1111/ajd.14067.
［12］	Verstockt B, Salas A, Sands BE, et al. IL⁃12 and IL⁃23 pathway inhibition in inflammatory bowel disease［J］. Nat Rev Gastroenterol Hepatol, 2023,20（7）:433⁃446. doi: 10.1038/s41575⁃023⁃00768⁃1.
［13］	Fanizza J, D'Amico F, Lusetti F, et al. The role of IL⁃23 inhibitors in Crohn's disease［J］. J Clin Med, 2023,13（1）:224. doi: 10.3390/jcm13010224.
［14］	Westerdahl JS, Nusbaum KB, Chung CG, et al. Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes［J］. J Dermatolog Treat, 2022,33（4）:2386⁃2390. doi: 10.1080/0954 6634.2021.1937475.
［15］	Burgdorf B, Schlott S, Ivanov IH, et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab［J］. Int Wound J, 2020,17（4）:1086⁃1088. doi: 10.1111/iwj.13359.
［16］	Reese AM, Erickson K, Reed KB, et al. Modified dose of guselkumab for treatment of pyoderma gangrenosum［J］. JAAD Case Rep, 2022,21:38⁃42. doi: 10.1016/j.jdcr.2021.11.030.
［17］	Chen Y, Ye X, Escames G, et al. The NLRP3 inflammasome: contributions to inflammation⁃related diseases［J］. Cell Mol Biol Lett, 2023,28（1）:51. doi: 10.1186/s11658⁃023⁃00462⁃9.
［18］	Jatana S, Ponti AK, Johnson EE, et al. A novel murine model of pyoderma gangrenosum reveals that inflammatory skin⁃gut crosstalk is mediated by IL⁃1β⁃primed neutrophils［J］. Front Immunol, 2023,14:1148893. doi: 10.3389/fimmu.2023.1148893.
［19］	O'Connor C, Gallagher C, Hollywood A, et al. Anakinra for recalcitrant pyoderma gangrenosum［J］. Clin Exp Dermatol, 2021,46（8）:1558⁃1560. doi: 10.1111/ced.14809.
［20］	Ben Abdallah H, Fogh K, Vestergaard C, et al. Pyoderma gangrenosum and interleukin inhibitors: a semi⁃systematic review［J］. Dermatology, 2022,238（4）:785⁃792. doi: 10.1159/00051 9320.
［21］	McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: a case report［J］. SAGE Open Med Case Rep, 2020,8:2050313X20940430. doi: 10.1177/2050313X20940430.
［22］	Tee MW, Avarbock AB, Ungar J, et al. Rapid resolution of pyoderma gangrenosum with brodalumab therapy［J］. JAAD Case Rep, 2020,6（11）:1167⁃1169. doi: 10.1016/j.jdcr.2020.08.033.
［23］	Kao AS, King AD, Daveluy S. Successful treatment of cabozantinib⁃induced pyoderma gangrenosum with ixekizumab therapy: a case report［J］. Dermatol Ther, 2022,35（9）:e15716. doi: 10.1111/dth.15716.
［24］	Dissemond J, Marzano AV, Hampton PJ, et al. Pyoderma gangrenosum: treatment options［J］. Drugs, 2023,83（14）:1255⁃1267. doi: 10.1007/s40265⁃023⁃01931⁃3.
［25］	Deng Z, Wang S, Wu C, et al. IL⁃17 inhibitor⁃associated inflammatory bowel disease: a study based on literature and database analysis［J］. Front Pharmacol, 2023,14:1124628. doi: 10.3389/fphar.2023.1124628.
［26］	Salas A, Hernandez⁃Rocha C, Duijvestein M, et al. JAK⁃STAT pathway targeting for the treatment of inflammatory bowel disease［J］. Nat Rev Gastroenterol Hepatol, 2020,17（6）:323⁃337. doi: 10.1038/s41575⁃020⁃0273⁃0.
［27］	Herrera⁃deGuise C, Serra⁃Ruiz X, Lastiri E, et al. JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases［J］. Front Med （Lausanne）, 2023,10:1089099. doi: 10. 3389/fmed.2023.1089099.
［28］	Castro L. JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum［J］. Int J Dermatol, 2023,62（8）:1088⁃1093. doi: 10.1111/ijd.16676.
［29］	Kridin K, Ankary⁃Khaner M, Kridin M, et al. Hematological malignancy⁃associated pyoderma gangrenosum: evaluating the magnitude of the association［J］. Front Med （Lausanne）, 2024,11:1425454. doi: 10.3389/fmed.2024.1425454.
［30］	Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review［J］. J Eur Acad Dermatol Venereol, 2009,23（9）:1008⁃1017. doi: 10.1111/j.1468⁃3083. 2009.03199.x.
［31］	Montagnon CM, Fracica EA, Patel AA, et al. Pyoderma gangrenosum in hematologic malignancies: a systematic review［J］. J Am Acad Dermatol, 2020,82（6）:1346⁃1359. doi: 10.1016/j.jaad.2019.09.032.
［32］	Martins M, Barbosa J, Eusébio SP, et al. From the deep: overlap of neutrophilic dermatoses disorders associated with acute myeloid leukemia［J］. Cureus, 2023,15（1）:e33456. doi: 10.7759/cureus.33456.
［33］	Szalat R, Monsel G, Le Goff W, et al. The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: association with IgA isotype and inflammatory profile［J］. J Am Acad Dermatol, 2015,73（5）:809⁃820. doi: 10.1016/j.jaad.2015. 07.031.
［34］	Maglie R, Genovese G, Solimani F, et al. Immune⁃mediated dermatoses in patients with haematological malignancies: a comprehensive review［J］. Am J Clin Dermatol, 2020,21（6）:833⁃854. doi: 10.1007/s40257⁃020⁃00553⁃9.
［35］	Parrondo RD, Iqbal M, Von Roemeling R, et al. IRAK⁃4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies［J］. Front Immunol, 2023,14:1239082. doi: 10.3389/fimmu.2023.1239082.
［36］	Ferrarini I, Rigo A, Zamò A, et al. Classical Hodgkin lymphoma cells may promote an IL⁃17⁃enriched microenvironment［J］. Leuk Lymphoma, 2019,60（14）:3395⁃3405. doi: 10.1080/1042 8194.2019.1636983.
［37］	Wang F, Li Y, Yang Z, et al. Targeting IL⁃17A enhances imatinib efficacy in Philadelphia chromosome⁃positive B⁃cell acute lymphoblastic leukemia［J］. Nat Commun, 2024,15（1）:203. doi: 10.1038/s41467⁃023⁃44270⁃3.
［38］	Yu S, Jiang J. Immune infiltration⁃related genes regulate the progression of AML by invading the bone marrow microenvironment［J］. Front Immunol, 2024,15:1409945. doi: 10.3389/fimmu.2024.1409945.
［39］	Blicharz L, Czuwara J, Rudnicka L, et al. Autoinflammatory keratinization diseases⁃the concept, pathophysiology, and clinical implications［J］. Clin Rev Allergy Immunol, 2023,65（3）:377⁃402. doi: 10.1007/s12016⁃023⁃08971⁃3.
［40］	Wouters F, Bogie J, Wullaert A, et al. Recent insights in pyrin inflammasome activation: identifying potential novel therapeutic approaches in pyrin⁃associated autoinflammatory syndromes［J］. J Clin Immunol, 2023,44（1）:8. doi: 10.1007/s10875⁃023⁃01621⁃5.
［41］	D'Onghia M, Malvaso D, Galluccio G, et al. Evidence on hidradenitis suppurativa as an autoinflammatory skin disease［J］. J Clin Med, 2024,13（17）:5211. doi: 10.3390/jcm13175211.
［42］	Yamanaka K. New treatment of pyoderma gangrenosum and hidradenitis suppurativa: a review［J］. J Dermatol, 2024,51（2）:172⁃179. doi: 10.1111/1346⁃8138.17031.
［43］	Brandão L, Moura RR, Marzano AV, et al. Variant enrichment analysis to explore pathways functionality in complex autoinflammatory skin disorders through whole exome sequencing analysis［J］. Int J Mol Sci, 2022,23（4）:2278. doi: 10.3390/ijms23042278.
［44］	Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment［J］. Am J Clin Dermatol, 2017,18（4）:555⁃562. doi: 10.1007/s40257⁃017⁃0265⁃1.
［45］	Chokoeva AA, Cardoso JC, Wollina U, et al. Pyoderma gangrenosum⁃a novel approach?［J］. Wien Med Wochenschr, 2017,167（3⁃4）:58⁃65. doi: 10.1007/s10354⁃016⁃0472⁃z.
［46］	Xu A, Strunk A, Garg A, et al. Prevalence of inflammatory bowel disease in patients with pyoderma gangrenosum: a population⁃based analysis［J］. J Am Acad Dermatol, 2022,86（6）:1351⁃1352. doi: 10.1016/j.jaad.2021.05.006.
［47］	Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients［J］. Br J Dermatol, 2011,165（6）:1244⁃1250. doi: 10.1111/j.1365⁃2133.2011.10565.x.
［48］	Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta⁃analysis［J］. Am J Clin Dermatol, 2018,19（4）:479⁃487. doi: 10.1007/s40257⁃018⁃0356⁃7.
［49］	Kridin K, Damiani G, Cohen AD. Rheumatoid arthritis and pyoderma gangrenosum: a population⁃based case⁃control study［J］. Clin Rheumatol, 2021,40（2）:521⁃528. doi: 10.1007/s10067⁃020⁃05253⁃7.
［50］	Cugno M, Gualtierotti R, Meroni PL, et al. Inflammatory joint disorders and neutrophilic dermatoses: a comprehensive review［J］. Clin Rev Allergy Immunol, 2018,54（2）:269⁃281. doi: 10. 1007/s12016⁃017⁃8629⁃0.
［51］	Weber B, Liao KP. Evidence for biologic drug modifying anti⁃rheumatoid drugs and association with cardiovascular disease risk mitigation in inflammatory arthritis［J］. Rheum Dis Clin North Am, 2023,49（1）:165⁃178. doi: 10.1016/j.rdc.2022.08.005.
［52］	Maalouf D, Battistella M, Bouaziz JD. Neutrophilic dermatosis: disease mechanism and treatment［J］. Curr Opin Hematol, 2015,22（1）:23⁃29. doi: 10.1097/MOH.0000000000000100.
［53］	Sawka E, Zhou A, Latour E, et al. Inflammatory arthritis⁃associated pyoderma gangrenosum: a systematic review［J］. Clin Rheumatol, 2021,40（10）:3963⁃3969. doi: 10.1007/s10067⁃021⁃05768⁃7.
［54］	Xing F, Chiu KH, Yang J, et al. Pyoderma gangrenosum with pulmonary involvement: a pulmonary special report and literature review［J］. Expert Rev Respir Med, 2022,16（2）:149⁃159. doi: 10.1080/17476348.2022.2027756.
［55］	Shavit E, Dagan O, Cohen AD, et al. Risk of cardiovascular diseases in pyoderma gangrenosum: a population⁃based study［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:e197⁃e199. doi: 10.1111/jdv.18527.
［56］	Gillard M, Anuset D, Maillard H, et al. Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients［J］. Br J Dermatol, 2018,179（1）:218⁃219. doi: 10. 1111/bjd.16463.
［57］	Zaino ML, Schadt CR, Callen JP, et al. Pyoderma gangrenosum: diagnostic criteria, subtypes, systemic associations, and workup［J］. Dermatol Clin, 2024,42（2）:157⁃170. doi: 10.1016/j.det. 2023.08.003.
［58］	Kridin K, Solomon A, Britva RL, et al. Chronic renal comorbidities in pyoderma gangrenosum: a retrospective cohort study［J］. Immunol Res, 2021,69（3）:249⁃254. doi: 10.1007/s12026⁃021⁃09187⁃3.
［59］	Al Ghazal P, Herberger K, Schaller J, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients［J］. Orphanet J Rare Dis, 2013,8:136. doi: 10.1186/1750⁃1172⁃8⁃136.
［60］	Shah M, Sachdeva M, Gefri A, et al. Paraneoplastic pyoderma gangrenosum in solid organ malignancy: a literature review［J］. Int J Dermatol, 2020,59（2）:154⁃158. doi: 10.1111/ijd.14637.
［61］	Kridin K, Laufer Britva R, Tzur Bitan D, et al. Is pyoderma gangrenosum associated with solid malignancies? Insights from a population⁃based cohort study［J］. Australas J Dermatol, 2021,62（3）:336⁃341. doi: 10.1111/ajd.13631.
［62］	Ravi M, Trinidad J, Spaccarelli N, et al. The impact of comorbidity identification on outcomes in patients with pyoderma gangrenosum: a retrospective cohort study of previously hospitalized patients［J］. J Am Acad Dermatol, 2022,87（1）:194⁃197. doi: 10.1016/j.jaad.2021.07.032.

[1]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 特应性皮炎达标门诊建设标准专家共识（2025基层版）[J]. 中华皮肤科杂志, 2025, 0(4): 20240296-e20240296.
[2]	李紫钰鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383.
[3]	吕铭悦满孝勇. 细胞治疗在系统性红斑狼疮中的应用[J]. 中华皮肤科杂志, 2025, 58(4): 374-377.
[4]	包诗杰韩梅周小勇. 基于文献回顾的依那西普治疗中毒性表皮坏死松解症疗效影响因素分析[J]. 中华皮肤科杂志, 2025, 58(4): 352-355.
[5]	万勇军杨海晶严翘陈梅王逢源粟倩雅董正邦王飞. 免疫检查点抑制剂相关Stevens-Johnson综合征/中毒性表皮坏死松解症9例临床及预后分析[J]. 中华皮肤科杂志, 2025, 58(4): 347-351.
[6]	中国医师协会皮肤科医师分会儿童学组中华医学会皮肤性病学分会银屑病学组. 【开放获取】儿童脓疱型银屑病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 297-306.
[7]	木葵郭慧文海泉龙海刘昱罗帅寒天黄馨周星雨肖嵘李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327.
[8]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会国家皮肤与免疫疾病临床医学研究中心. 【开放获取】副肿瘤性天疱疮诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 289-296.
[9]	许焯红胡煜顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 0(3): 20220881-e20220881.
[10]	袁勇勇潘萌. 家族性慢性良性天疱疮研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240182-e20240182.
[11]	叶慧邓仕琳梁景耀张锡宝. 特应性皮炎复发控制与组织驻留记忆性T细胞的相关性研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240192-e20240192.
[12]	李翔倩张建中周城. 系统小分子药物和生物制剂治疗斑秃的临床研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240247-e20240247.
[13]	王文秋李承新王睿. 生物制剂治疗银屑病复发的研究现状[J]. 中华皮肤科杂志, 2025, 0(3): 20230301-e20230301.
[14]	陈启韬李煜乾邵光辉朱晶朱麒麟李中明杜旭峰范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 272-275.
[15]	蒋佳怡王大光. 系统性疾病致甲改变机制研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 282-285.

坏疽性脓皮病系统合并症的研究进展

Pyoderma gangrenosum-related systemic complications

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 62

相关文章 15

Metrics

本文评价

推荐阅读 10